Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Orphan Drug

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536205

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536205

Sickle-Cell Anemia Therapeutics

PUBLISHED:
PAGES: 181 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5450
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16350

Add to Cart

Description

Table of Contents

Global Sickle-Cell Anemia Therapeutics Market to Reach US$4.9 Billion by 2030

The global market for Sickle-Cell Anemia Therapeutics estimated at US$2.1 Billion in the year 2023, is expected to reach US$4.9 Billion by 2030, growing at a CAGR of 12.5% over the analysis period 2023-2030. Hydroxyurea Drug, one of the segments analyzed in the report, is expected to record a 12.0% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Oxbryta Drug segment is estimated at 12.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$581.5 Million While China is Forecast to Grow at 20.8% CAGR

The Sickle-Cell Anemia Therapeutics market in the U.S. is estimated at US$581.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 20.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.6% and 10.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Global Sickle-Cell Anemia Therapeutics Market - Key Trends and Drivers Summarized

Sickle-cell anemia is a genetic blood disorder characterized by the presence of abnormal hemoglobin, known as hemoglobin S, which distorts red blood cells into a sickle shape. These misshapen cells can block blood flow, leading to pain, infections, acute chest syndrome, stroke, and other severe complications. The standard treatment has long been focused on managing symptoms and preventing complications, with options like pain relief medications, antibiotics, and blood transfusions. Hydroxyurea, a drug that induces the production of fetal hemoglobin, has been the mainstay of disease-modifying therapy, reducing the frequency of painful crises and acute chest syndrome. Bone marrow transplants offer a potential cure but are limited by donor availability and the risks associated with the procedure.

Recent advancements in sickle-cell anemia therapeutics are promising, bringing hope for more effective and curative treatments. Gene therapy has emerged as a groundbreaking approach, with several clinical trials demonstrating the potential to correct the genetic defect responsible for the disease. Techniques such as CRISPR-Cas9 gene editing and lentiviral vector-mediated gene addition are at the forefront of these innovations. Additionally, new drug therapies are being developed to target the underlying pathophysiology of sickle-cell disease. These include voxelotor, which increases hemoglobin's affinity for oxygen, and crizanlizumab, a monoclonal antibody that prevents the adhesion of sickle cells to blood vessel walls, thereby reducing vaso-occlusive episodes. The pipeline for sickle-cell therapeutics is robust, with numerous investigational drugs in various stages of development.

The growth in the sickle-cell anemia therapeutics market is driven by several factors. Technological advancements in gene therapy and genome editing are expanding treatment possibilities and improving efficacy. The increasing prevalence of sickle-cell anemia, particularly in regions with high rates of the disease, such as sub-Saharan Africa, India, the Middle East, and certain parts of the United States, is driving demand for effective treatments. Enhanced diagnostic capabilities are facilitating early detection and intervention, which is crucial for managing the disease and improving patient outcomes. Significant investments in research and development by pharmaceutical companies are accelerating the discovery and commercialization of novel therapies. Regulatory support, including orphan drug designations and fast-track approvals, is facilitating quicker access to new treatments. Additionally, the growing adoption of precision medicine is generating demand for personalized therapies tailored to individual genetic profiles. Patient advocacy groups and public health initiatives are also playing a vital role in raising awareness, promoting early diagnosis, and supporting the adoption of innovative treatments, thereby contributing to the overall growth of the sickle-cell anemia therapeutics market.

Select Competitors (Total 86 Featured) -

  • Agios Pharmaceuticals, Inc.
  • Beam Therapeutics
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Chiesi Global Rare Disease
  • CRISPR Therapeutics
  • CSL Ltd.
  • Editas Medicine, Inc.
  • Emmaus Life Sciences, Inc.
  • GSK Plc
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Vertex Pharmaceuticals Inc.
Show more
Product Code: MCP26843

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Sickle-Cell Anemia Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Sickle-Cell Anemia Spurs Growth in Therapeutics Market
    • Advances in Gene Therapy Propel Growth
    • CRISPR Technology Expands Addressable Market Opportunity
    • Improved Diagnostic Techniques Generate New Opportunities
    • Here's How Personalized Medicine is Transforming the Market
    • Increasing Awareness Throws the Spotlight on Early Diagnosis and Treatment
    • Expanding Global Healthcare Infrastructure Drives Adoption in Emerging Markets
    • Biotechnology Innovations Propel Growth in Curative Therapies
    • Increasing Use of Artificial Intelligence in Drug Discovery Spurs Innovation
    • Technological Advancements in Blood Transfusion Techniques Generate Demand
    • Economic Burden of Sickle-Cell Disease Strengthens Business Case for Effective Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sickle-Cell Anemia Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sickle-Cell Anemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hydroxyurea Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hydroxyurea Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hydroxyurea Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Oxbryta Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Oxbryta Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Oxbryta Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adakveo Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adakveo Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Adakveo Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • CHINA
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Sickle-Cell Anemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Spain 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Russia 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Sickle-Cell Anemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Australia 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • INDIA
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: India 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: South Korea 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Sickle-Cell Anemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Argentina 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Brazil 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Mexico 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Latin America 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Sickle-Cell Anemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Iran 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Israel 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Saudi Arabia 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UAE 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Middle East 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Sickle-Cell Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Sickle-Cell Anemia Therapeutics by Drug Type - Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Africa 16-Year Perspective for Sickle-Cell Anemia Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea Drug, Oxbryta Drug, Adakveo Drug and Other Drug Types for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!